Terms: = Lung cancer AND ERCC5, XPGC, 2073, ENSG00000134899, RP11-484I6_5, COFS3, XPG, UVDR, ERCM2 AND Prognosis
9398 results:
1. Bone mineral density as an individual prognostic biomarker in NSCLC patients treated with immune checkpoint inhibitors.
Lou J; Gong B; Li Y; Guo Y; Li L; Wang J; Liu W; You Z; Zhang H; Pan F; Liang B; Yang L; Zhou G
Front Immunol; 2024; 15():1332303. PubMed ID: 38698843
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic Implications of Small Cell lung cancer Transcriptional Subtyping for CNS Metastases.
Tringale KR; Skakodub A; Egger J; Eichholz J; Yu Y; Gomez D; Rimner A; Li B; Yamada Y; Wilcox J; Moss N; Imber BS; Rekhtman N; Baine MK; Rudin CM; Pike LRG
JCO Precis Oncol; 2024 Apr; 8():e2300470. PubMed ID: 38691815
[TBL] [Abstract] [Full Text] [Related]
3. Role of antihypertensive medicines in prostate cancer: a systematic review.
Iheanacho CO; Enechukwu OH
BMC Cancer; 2024 Apr; 24(1):542. PubMed ID: 38684963
[TBL] [Abstract] [Full Text] [Related]
4. Misdiagnosed Asthma Turned Out to Be Bronchial Fibroepithelial Polyp: Case Report and Review of Literature.
Salahaldeen D; Hanin S; Dana S; Dana A; Khalil W; Mohammad F; Yousef A
J Investig Med High Impact Case Rep; 2024; 12():23247096241248981. PubMed ID: 38682757
[TBL] [Abstract] [Full Text] [Related]
5. [Interpretation of global lung cancer statistics].
Cai L; Zhu CX; Zhang XL; Fang Y; Yang HY; Guo LW
Zhonghua Liu Xing Bing Xue Za Zhi; 2024 Apr; 45(4):585-590. PubMed ID: 38678357
[TBL] [Abstract] [Full Text] [Related]
6. Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in lung Adenocarcinoma and Squamous Cell Carcinoma.
Koh YW; Han JH; Haam S; Lee HW
Anticancer Res; 2024 May; 44(5):2081-2089. PubMed ID: 38677736
[TBL] [Abstract] [Full Text] [Related]
7. Smoking, lung cancer Stage, and Prognostic Factors-Findings from the National lung Screening Trial.
Zhu J; Branstetter S; Lazarus P; Muscat JE
Int J Environ Res Public Health; 2024 Mar; 21(4):. PubMed ID: 38673313
[TBL] [Abstract] [Full Text] [Related]
8. The impact of COVID-19 on the prognosis of deep vein thrombosis following anticoagulation treatment: a two-year single-center retrospective cohort study.
Wang Q; Wu J; Zhang P; Ma X
BMC Pulm Med; 2024 Apr; 24(1):208. PubMed ID: 38671424
[TBL] [Abstract] [Full Text] [Related]
9. Brain radiotherapy and anlotinib control primary cardiac angiosarcoma with metastases: A case report.
Ma YY; Li ZK; Liao ZY; Peng Y; Zeng L; Ma DY
Medicine (Baltimore); 2024 Apr; 103(17):e37914. PubMed ID: 38669418
[TBL] [Abstract] [Full Text] [Related]
10. Limited resection is comparable to lobectomy for tumor size ≤ 2 cm pulmonary invasive mucinous adenocarcinoma.
Lin W; Su H; Xie H; Xu L; Wang T; Wang L; Hu X; Zhao D; Zhu Y; Wang H; Jiang G; Xie D; Chen C;
World J Surg Oncol; 2024 Apr; 22(1):109. PubMed ID: 38664816
[TBL] [Abstract] [Full Text] [Related]
11. High core 1β1,3-galactosyltransferase 1 expression is associated with poor prognosis and promotes cellular radioresistance in lung adenocarcinoma.
Chen Y; Ji Y; Shen L; Li Y; Ren Y; Shi H; Li Y; Wu Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):214. PubMed ID: 38662050
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
13. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.
Zhang W; Liang Z; Zhao Y; Li Y; Chen T; Li W; Chen Y; Wu P; Zhang H; Fang C; Li L
Front Immunol; 2024; 15():1359302. PubMed ID: 38646542
[TBL] [Abstract] [Full Text] [Related]
14. Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses.
Xu K; Lu W; Yu A; Wu H; He J
BMC Cancer; 2024 Apr; 24(1):491. PubMed ID: 38632512
[TBL] [Abstract] [Full Text] [Related]
15. Analysis of 25 surgical cases of thymic neuroendocrine tumors and thymic carcinoma.
Midorikawa K; Miyahara S; Nishino N; Ueda Y; Waseda R; Shiraishi T; Sato T
J Cardiothorac Surg; 2024 Apr; 19(1):225. PubMed ID: 38627811
[TBL] [Abstract] [Full Text] [Related]
16. Integrated analysis highlights the significance role of ITGAL in lung adenocarcinoma.
Xiao Z; Nian Z; Zhang M; Liu Z; Liu Z; Zhang Z
J Cell Mol Med; 2024 Apr; 28(8):e18289. PubMed ID: 38613346
[TBL] [Abstract] [Full Text] [Related]
17. Dichotomous Effects of Glypican-4 on cancer Progression and Its Crosstalk with Oncogenes.
Chérouvrier Hansson V; Cheng F; Georgolopoulos G; Mani K
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612755
[TBL] [Abstract] [Full Text] [Related]
18. Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients.
Xu Y; Zhang Q; Chen Z; Yang S; Chen H; Xiao X; Jiang H
BMC Pulm Med; 2024 Apr; 24(1):174. PubMed ID: 38609918
[TBL] [Abstract] [Full Text] [Related]
19. The characteristics and prognosis of different disease patterns of multiple primary lung cancers categorized according to the 8th edition lung cancer staging system.
Wang Y; Fang L; Hu X; Wu H; Zhou L; Xue Q; Gao S; He J
J Cardiothorac Surg; 2024 Apr; 19(1):200. PubMed ID: 38600565
[TBL] [Abstract] [Full Text] [Related]
20. Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data.
Hong S; Lee JH; Heo JY; Suh KJ; Kim SH; Kim YJ; Kim JH
J Cancer Res Clin Oncol; 2024 Apr; 150(4):186. PubMed ID: 38600328
[TBL] [Abstract] [Full Text] [Related]
[Next]
